Immunotherapy for hepatocellular carcinoma
AssigneeBeiGene, Ltd.
InventorsLai Wang, Kang Li, Qinzhou Qi, Jeannie Hou, Zhong Wu
Life of this patent
Estimating the term…
Abstract
Disclosed herein is method for the prevention, delay of progression or treatment of hepatocellular carcinoma in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an anti-PD-1 antibody, which is an antibody or a fragment antigen binding thereof, specifically binding to human PD-1.
Claims13
A method of treating hepatocellular carcinoma (HCC) in a human patient in need thereof, the method comprising administering to the human patient a therapeutically effective amount of an anti-PD-1 antibody or an antigen binding fragment thereof, comprising heavy chain complementarity determining regions CDR-H1, CDR-H2, and CDR-H3 comprising SEQ ID NOs:
- 31, 32, and 33, respectively;
- light chain complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 comprising SEQ ID NOs:
- 34, 35, and 36, respectively;
- and an IgG4 heavy chain constant domain comprising SEQ ID NO:88;
- and wherein the administering is performed parenterally at a dose of 0.5-10 mg/kg Q2W or Q3W.
Dependencies are inferred from the claim text.